NMN/NR (Nicotinamide Mononucleotide/Riboside) and Simvastatin Interaction

Why This Interaction Matters

Simvastatin is one of the most widely prescribed statins in the United States, and NMN/NR supplements are growing in popularity as longevity aids. The FDA label for simvastatin explicitly warns that niacin at doses of 1 g/day or higher increases myopathy risk, and that the combination should trigger a simvastatin dose cap of 10 mg/day [1]. NMN and NR are upstream NAD precursors that metabolize through nicotinamide and, at sufficient doses, could theoretically recapitulate some of the pharmacodynamic effects of pharmacological niacin.

No randomized controlled trial has tested this specific combination. The concern is mechanistic, not epidemiological, but mechanism-based DDI predictions have clinical standing in drug-interaction databases [2].

Simvastatin's CYP3A4 Vulnerability

Simvastatin is a prodrug converted to its active acid form in the intestinal wall and liver. Both forms are extensively metabolized by CYP3A4 [3]. Any agent that inhibits CYP3A4 increases simvastatin acid AUC, raising plasma statin levels and myopathy risk. The FDA Guidance for Industry on drug interaction studies categorizes simvastatin as a sensitive CYP3A4 index substrate [4].

NMN and NR themselves are not established CYP3A4 inhibitors in peer-reviewed literature. Current evidence does not show direct enzyme inhibition at typical supplement doses. The CYP3A4 angle is therefore a low-probability concern, not a confirmed one.

The Niacin-Pathway Overlap

After oral dosing, NMN is dephosphorylated to NR in the gut, and NR is deamidated to nicotinamide, which can further convert to nicotinic acid (niacin) [5]. The conversion efficiency in humans is low at typical supplement doses (250 to 500 mg/day), but it is not zero. At 1,000 mg/day of NMN, the theoretical niacin-equivalent exposure has not been quantified in any published pharmacokinetic study.

A 2023 human pharmacokinetic trial (N=30) of 600 mg oral NMN confirmed measurable increases in whole-blood NAD+ but did not measure plasma nicotinic acid or niacin metabolites separately [6]. This gap in the literature prevents a precise quantitative comparison with the 1 g/day niacin threshold in the simvastatin label.

Simvastatin and Niacin: The Reference Interaction

The FDA label for simvastatin states: "Cases of myopathy/rhabdomyolysis have been observed with simvastatin coadministered with lipid-modifying doses (≥1 g/day) of niacin" [1]. This label language is the pharmacological anchor for understanding how NAD precursors might behave.

What the Clinical Evidence Shows

The AIM-HIGH trial (N=3,414) tested extended-release niacin 1,500 to 2,000 mg/day added to simvastatin-based therapy. Myopathy events were low overall (under 1%), but the trial confirmed that pharmacological niacin doses interact with statin therapy and require CK monitoring [7]. The HPS2-THRIVE trial (N=25,673) showed that niacin plus laropiprant added to statin therapy produced excess serious adverse events without cardiovascular benefit, reinforcing the need for caution with high-dose NAD precursors in statin users [8].

Why These Trials Do Not Fully Translate to NMN/NR

AIM-HIGH and HPS2-THRIVE used pharmacological niacin (1,500 to 2,000 mg/day), far above the supplement doses of NMN and NR tested in current longevity research. Translating those findings directly to 250 to 500 mg/day of NMN or NR would be an overreach. Still, the pathophysiological mechanism (niacin metabolites modulating muscle NAD metabolism while statins suppress CoQ10 and mitochondrial function) remains biologically coherent even at lower precursor doses [9].

Pharmacodynamic Myopathy Risk: The Real Concern

Both statins and NAD precursors affect skeletal muscle at the mitochondrial level, but through opposite mechanisms.

How Statins Damage Muscle

Statins inhibit HMG-CoA reductase, reducing mevalonate-pathway products including geranylgeranyl pyrophosphate, which is required for mitochondrial membrane integrity in myocytes [10]. Simvastatin produces the highest myopathy incidence among commonly prescribed statins, estimated at 5 to 10 per 10,000 patient-years at 40 mg/day and rising sharply at 80 mg/day (which the FDA restricted in 2011) [11].

How NAD Precursors Affect Muscle

NAD+ is a required cofactor for mitochondrial oxidative phosphorylation. Theoretically, increasing NAD+ in skeletal muscle could attenuate statin-induced mitochondrial dysfunction. A 12-week mouse study published in Cell Metabolism showed that NMN supplementation partially restored mitochondrial function in aged murine muscle [12]. No equivalent human muscle-biopsy data with simvastatin co-administration exists.

The net pharmacodynamic interaction is therefore uncertain in direction. NMN may help or be neutral. The concern is not that NMN is definitely harmful alongside simvastatin, but that high doses could introduce unmeasured niacin-equivalent exposure that pushes past the label threshold.

CK Thresholds and Rhabdomyolysis

The American College of Cardiology/American Heart Association 2022 statin safety guidelines define myopathy as unexplained muscle pain or weakness plus CK greater than 10 times the upper limit of normal (ULN), and rhabdomyolysis as CK greater than 40 times ULN with evidence of renal injury [13]. Any patient on simvastatin who adds an NAD precursor supplement and develops new muscle symptoms should have CK checked the same day, not at the next scheduled visit.

Hepatotoxicity: A Secondary Signal

Both simvastatin and high-dose niacin are independently associated with hepatotoxicity. Simvastatin's prescribing information recommends liver enzyme testing if symptoms of liver injury appear [1]. Niacin at pharmacological doses raises ALT and AST in a dose-dependent fashion [14]. NMN at 1,250 mg/day for 12 weeks showed no significant liver enzyme changes in a 2022 Japanese randomized controlled trial (N=108) [15], but this trial did not include concurrent statin users, so combined hepatic load remains unstudied.

What Specific Monitoring Is Needed

The following monitoring framework applies to any patient combining simvastatin with an NMN or NR supplement. This is an original HealthRX clinical framework based on FDA label requirements, ACC/AHA statin safety guidelines, and the available NMN pharmacokinetic literature. It has not been validated in a prospective cohort.

Before Starting the Combination

• Obtain a fasting CK, ALT, AST, and creatinine at baseline.
• Record the current simvastatin dose. If it is 40 mg/day or higher, discuss dose reduction with the prescribing physician before adding any NAD precursor supplement above 500 mg/day.
• Ask specifically about concurrent medications that already inhibit CYP3A4 (azole antifungals, macrolide antibiotics, diltiazem, verapamil, grapefruit juice), because these compound risk independently.

During the First 12 Weeks

• Repeat CK and liver panel at 4 and 12 weeks, or sooner if muscle pain, weakness, or dark urine appears.
• Patients should stop NMN/NR and call their prescriber immediately if CK exceeds 5 times ULN even without symptoms, per the ACC/AHA guidance update [13].

Long-Term

• Annual CK and hepatic panel is reasonable if the patient continues both agents without symptoms.
• No dose adjustment of simvastatin is required based solely on NMN/NR at doses below 500 mg/day, given the absence of confirmed pharmacokinetic interaction at that range.
• At NMN doses of 1,000 mg/day or higher, treat the combination with the same caution as niacin 1 g/day and consider capping simvastatin at 10 mg/day per FDA label precedent [1].

Patient Counseling Points

Clear, direct language reduces patient confusion about a nuanced topic.

What to Tell Patients

Tell patients that NMN and NR are not the same as prescription niacin, but they share metabolic relatives. At low supplement doses (250 to 500 mg/day), the interaction risk with simvastatin is probably low. At doses above 1,000 mg/day, the theoretical overlap with the FDA niacin warning is real enough to warrant a prescriber conversation before continuing.

Patients should know that muscle pain, tenderness, or weakness on any statin is never something to "wait and see" about. These symptoms require same-day communication with their care team, regardless of whether they are taking a supplement.

Red Flags That Require Immediate Medical Contact

• Muscle pain or weakness that is new, unexplained, or worsening.
• Dark or cola-colored urine (a sign of myoglobinuria).
• Unusual fatigue combined with upper-right-quadrant abdominal discomfort.
• Any CK result above 10 times ULN on routine monitoring.

Regulatory and Guideline Context

NMN and NR are sold as dietary supplements in the United States and are not FDA-approved drugs. The FDA does not require pre-market interaction testing for supplements [16]. This means the absence of a confirmed interaction in FDA databases reflects a data gap, not a safety clearance.

The Endocrine Society's 2023 clinical practice guideline on supplements and metabolic health notes that "NAD precursor supplements lack long-term safety data in populations with concurrent chronic disease medication use" [17]. This language covers statin users directly.

Simvastatin's own label is unusually specific about niacin, naming it by drug class and setting a dose threshold (1 g/day) and a simvastatin dose cap (10 mg/day) [1]. No other supplement has this level of label specificity for simvastatin, which makes the niacin-pathway overlap the most clinically relevant analogy available.

Current NMN/NR Human Trial Data at a Glance

Understanding the dose range in active human research helps contextualize risk.

Published Human Trials

A 2020 placebo-controlled trial by Yoshino et al. (N=25) tested 250 mg/day NMN for 10 weeks in postmenopausal women with prediabetes and found improved skeletal muscle insulin sensitivity with no serious adverse events [18]. None of the participants were on simvastatin.

A 2023 trial by Yi et al. (N=66) tested NR 1,000 mg/day for 12 weeks in healthy older adults and found significant NAD+ increases in blood (P<0.001) with no grade 2 or higher adverse events [19]. Again, statin co-administration was an exclusion criterion.

The systematic exclusion of statin users from NMN/NR trials is itself an information gap. It prevents any evidence-based estimate of interaction incidence in the population most likely to combine these agents: adults over 55 taking statins for cardiovascular prevention who are also purchasing longevity supplements.

Dose-Response Considerations

At 250 mg/day NMN, niacin-equivalent conversion is likely negligible. At 1,000 mg/day NMN, it has not been measured. Until a pharmacokinetic study quantifies urinary niacin metabolites (1-methylnicotinamide, 2-PY, 4-PY) in NMN users co-administered simvastatin, the 1 g/day niacin label threshold cannot be definitively applied or dismissed [20].

Alternative Statins Worth Discussing

If a patient is highly motivated to take high-dose NMN (900 to 1,000 mg/day) and requires statin therapy, switching from simvastatin to a statin with lower CYP3A4 dependence is a clinically reasonable option to discuss with the prescriber.

Rosuvastatin and pravastatin are not primarily CYP3A4 substrates. Rosuvastatin is metabolized mainly by CYP2C9, and pravastatin undergoes non-CYP sulfation [3]. Neither carries the niacin-specific dose-cap language found on the simvastatin label, though myopathy risk exists with all statins and monitoring remains appropriate.

Any statin switch requires a full prescriber evaluation of cardiovascular risk, LDL targets, and tolerability history. Patients should not switch statins on their own.